DOLUTEGRAVIR efficacy in HIV infected patients

  • Dumitru I
  • Cernat R
  • Rugină S
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

In the past years there have been numerous discoveries regarding treatment of patients with HIV. If at first the doctors watched as patients live longer, now we want these patients to live better with regimens potent, safe, individualized and without side effects. HAART has revolutionized “the world HIV” and caused a significant reduction in mortality, and morbidity associated with HIV-related opportunistic infections. However, side effects associated with HAART, metabolic toxicity (such as abnormal fat distribution, abnormal lipid and glucose metabolism, and bone loss) and the large number of pills led to decreased patient adherence.

Cite

CITATION STYLE

APA

Dumitru, I. M., Cernat, R. C., & Rugină, S. (2015). DOLUTEGRAVIR efficacy in HIV infected patients. ARS Medica Tomitana, 21(1), 42–51. https://doi.org/10.1515/arsm-2015-0019

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free